OBJECTIVES : To investigate physicians’ reports of the healthcare resources and time needed to intensify type 2 diabetes (T2D) patients treated with basal insulin to basal-bolus insulin regimen. METHODS : A web-based survey was developed based on concept elicitation interviews with 16 physicians in the United Kingdom (UK) and the United States (USA). Cognitive interviews were conducted with 12 physicians, and usability testing was performed. A total of 458 physicians, including general practitioners (GPs) and specialists (diabetologists/endocrinologists), completed the survey. The analysis sample excluded physicians not experienced with intensifying T2D patients from basal insulin to basal-bolus (n=438; UK, n=215; USA, n=223). RESULTS : Physicians indicated that, on average, patients had 2.3 healthcare provider (HCP) visits [95% CI, 2.1-2.6] before agreeing/refusing to intensify to basal-bolus, which took 10.0 weeks [95% CI, 9.3-10.7]. On average, GPs reported referring 22.6% of T2D patients with uncontrolled HbA1c to specialists for intensification, and average wait time before intensification by a specialist was 8.4 weeks [95% CI, 7.7-9.1]. Physicians reported 2.1 HCP visits [95% CI, 2.0-2.2] for intensification training, which lasted 7.3 weeks [95% CI, 6.7-8.0], on average. Physicians indicated that an additional 2.6 HCP visits [95% CI, 2.4-2.7] were needed, on average, for titration to optimal dose after initial training, which took 12.7 weeks [95% CI, 12.0-13.4]. In total, intensification required 7.0 HCP visits [95% CI, 6.6-7.3] and 30.1 weeks [95% CI, 28.4-31.7], on average, excluding referral time. Among intensified patients, physicians reported that, on average, 57.0% reached their HbA1c target after 2.6 HCP visits [95% CI, 2.5-2.8] and 37.8% discontinued basal-bolus. CONCLUSIONS : Intensifying T2D patients to basal-bolus requires use of expensive healthcare resources and is time-consuming. Study limitations include possible overlap in the intensification training and titration process. Similar findings have been reported for the costs of intensifying T2D patients on basal insulin to basal with GLP-1.